Key Highlights

  • Clarivate (NYSE:CLVT) changed hands at USD 2.21 after a 4.19% advance in the latest session, and it has risen 22.72% over one week and 52.34% over one month, ranking sixteenth on a one-month small cap list.
  • Third-quarter adjusted diluted EPS came in at USD 0.21 against USD 0.18 a year earlier, a 16.7% rise, while Revenue from continuing operations slid 9.2% to USD 481.6 million.
  • Full-year 2026 guidance targets revenue of USD 1.965 billion to USD 1.985 billion, adjusted EBITDA of USD 865 million to USD 885 million and free Cash Flow of USD 320 million to USD 340 million.
  • The stock still shows a 21.11% loss over six months and a 34.45% decline year to date, while total Debt of USD 4,176.1 million is heavy for a company inside the USD 300 million to USD 2 billion small cap band.

Adjusted EPS Growth Around the November 3 Release

The shares closed the latest session at USD 2.21, a 4.19% rise, after climbing 22.72% over one week, 52.34% over one month and 18.12% over three months, according to a published market data snapshot dated November 5, 2026. Third-quarter results arrived on Tuesday, November 3, 2026, inside the weekly window. Adjusted diluted EPS of USD 0.21 rose 16.7% from USD 0.18, and adjusted Net Income went up 14.0% to USD 136.0 million from USD 119.3 million. Adjusted EBITDA from continuing operations declined 1.8% to USD 218.2 million, while free cash flow dipped to USD 110.2 million from USD 115.5 million. GAAP results were weaker: the net loss grew to USD 80.8 million, or USD 0.13 a share, from USD 28.3 million. Nine-month adjusted EPS came to USD 0.59, a 20.4% increase.

Profit Growth Against Shrinking Sales and Unconfirmed Guidance Changes

The release does not quote earlier guidance ranges, so a guidance raise cannot be confirmed. What it does show is profit growing while sales shrink, a pattern that can support a rebound from a long slide. Management guided 2026 adjusted diluted EPS to USD 0.73 to USD 0.77 and fourth-quarter EPS to USD 0.14 to USD 0.18. Fourth-quarter revenue is guided at USD 490 million to USD 510 million, with an adjusted EBITDA Margin of 44.0% to 46.0%. Annual contract value rose 3.6% overall and 1.8% on an organic basis. As general context, sector rotation, short covering and an adjusted EPS beat often drive moves like this, but no catalyst beyond the results has been identified.

Leverage and Buybacks Shape the Risk After a 52.34% Rally

At USD 2.21 the stock sits in the small cap bucket, where a few trades can move the price and spreads can be wide. The 52.34% monthly gain follows a 21.11% six-month loss and a 34.45% year-to-date decline, so the shares remain well below where 2026 began. Total debt was USD 4,176.1 million, down USD 293.8 million from the prior year-end, against cash of USD 257.0 million. Buybacks totaled USD 18.1 million in nine months, against USD 149.5 million a year earlier. Total revenue including divested units fell 5.3% to USD 1,740.7 million over nine months. A leveraged Balance Sheet magnifies share price swings, and the rebound can reverse. The 52-week range and average Volume were not verified.

Where Things Stand

Clarivate (NYSE:CLVT) rose on a results-led rebound after a deep drawdown, though no single catalyst beyond the November 3, 2026 release has been identified. Adjusted EPS of USD 0.21 beat the year-ago USD 0.18, yet continuing revenue fell 9.2% and total debt stands at USD 4,176.1 million. The stock ranks sixteenth on the one-month small cap list at USD 2.21. Thin trading and wide spreads mean the move may reverse, and nothing here suggests it will continue.